Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Alex F. Herrera et al.|Blood|2024Cited by 132
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Santosha A. Vardhana, Gunjan L. Shah et al.|Cancer Cell|2022Cited by 88
Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomasAndrew Jallouk, Sairah Ahmed, Lorenzo Falchi et al.|Blood|2025Cited by 0
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphomaPierre Stéphan, Jennifer L. Crombie, Karan Chohan et al.|Blood|2025Cited by 0
Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamabAllison M. Bock, Sairah Ahmed, Lei Feng et al.|Blood|2025Cited by 0